Philip G Conaghan, Michael A Bowes, Sarah R Kingsbury, Alan Brett, Gwenael Guillard, Biljana Rizoska, Niclas Sjögren, Philippa Graham, Åsa Jansson, Cecilia Wadell, Richard Bethell, John Öhd
BACKGROUND: MIV-711 is a novel selective cathepsin K inhibitor with beneficial effects on bone and cartilage in preclinical osteoarthritis models. OBJECTIVE: To evaluate the efficacy, safety, and tolerability of MIV-711 in participants with symptomatic, radiographic knee osteoarthritis. DESIGN: 26-week randomized, double-blind, placebo-controlled phase 2a study with a 26-week open-label safety extension substudy. (EudraCT: 2015-003230-26 and 2016-001096-73)...
January 21, 2020: Annals of Internal Medicine